Brokers Issue Forecasts for CRDL Q1 Earnings

Cardiol Therapeutics Inc. (NASDAQ:CRDL) – Investment analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Cardiol Therapeutics in a report issued on Thursday, April 2nd. HC Wainwright analyst B. Folkes anticipates that the company will earn ($0.06) per share for the quarter. HC Wainwright has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for Cardiol Therapeutics’ current full-year earnings is ($0.33) per share. HC Wainwright also issued estimates for Cardiol Therapeutics’ Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.27) EPS and FY2027 earnings at ($0.34) EPS.

A number of other brokerages have also commented on CRDL. Canaccord Genuity Group reiterated a “buy” rating and issued a $8.00 target price on shares of Cardiol Therapeutics in a research report on Monday. Wall Street Zen upgraded Cardiol Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday. Finally, upgraded Cardiol Therapeutics to a “strong-buy” rating in a research report on Tuesday, February 3rd. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Cardiol Therapeutics has an average rating of “Hold” and a consensus target price of $8.50.

Cardiol Therapeutics Price Performance

Shares of NASDAQ CRDL opened at $1.40 on Tuesday. The business’s 50 day moving average price is $1.07 and its 200 day moving average price is $1.05. The firm has a market cap of $156.55 million, a P/E ratio of -5.00 and a beta of 0.82. Cardiol Therapeutics has a 52 week low of $0.80 and a 52 week high of $1.59. The company has a quick ratio of 3.89, a current ratio of 3.89 and a debt-to-equity ratio of 0.01.

Cardiol Therapeutics (NASDAQ:CRDL) last issued its earnings results on Monday, March 30th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.04.

Institutional Investors Weigh In On Cardiol Therapeutics

Hedge funds have recently bought and sold shares of the stock. Security National Bank of Sioux City Iowa IA purchased a new stake in Cardiol Therapeutics in the 4th quarter worth approximately $31,000. Simplex Trading LLC boosted its position in Cardiol Therapeutics by 96.9% in the 4th quarter. Simplex Trading LLC now owns 32,197 shares of the company’s stock worth $31,000 after purchasing an additional 15,842 shares in the last quarter. Boyer Financial Services Inc. purchased a new stake in Cardiol Therapeutics in the 4th quarter worth approximately $33,000. Bank of America Corp DE boosted its position in Cardiol Therapeutics by 136.2% in the 2nd quarter. Bank of America Corp DE now owns 26,455 shares of the company’s stock worth $36,000 after purchasing an additional 15,255 shares in the last quarter. Finally, Susquehanna International Group LLP boosted its position in Cardiol Therapeutics by 366.5% in the 3rd quarter. Susquehanna International Group LLP now owns 93,398 shares of the company’s stock worth $100,000 after purchasing an additional 73,375 shares in the last quarter. Hedge funds and other institutional investors own 12.49% of the company’s stock.

Key Cardiol Therapeutics News

Here are the key news stories impacting Cardiol Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” and a $9.00 target, and materially tightened/raised its model — boosting FY2026 EPS from ($0.41) to ($0.27) and improving FY2027 to ($0.34) (from ($0.51)). The firm also laid out -$0.06 quarterly EPS assumptions across 2026, signaling a more constructive outlook. HC Wainwright estimates
• Positive Sentiment: Canaccord Genuity reaffirmed its “Buy” rating with an $8.00 price target, a substantially higher objective than current levels — reinforcing bullish sentiment among institutional brokers. Benzinga article
• Neutral Sentiment: HC Wainwright’s published quarter-by-quarter EPS assumptions (Q1–Q4 2026 at ~$0.06 loss per share) provide a consistent near-term earnings path but do not introduce new catalysts beyond the improved FY guidance. HC Wainwright quarterly estimates
• Negative Sentiment: Brookline Capital trimmed several near-term estimates: Q3 2026 EPS lowered to ($0.08) from ($0.07), Q4 to ($0.09) and FY2026 to ($0.31) (from $0.29 prior). These downgrades introduce some caution about near-term results and pressure investor expectations. Brookline estimate changes

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc (NASDAQ: CRDL) is a clinical-stage pharmaceutical company dedicated to developing immunomodulatory treatments for patients with cardiovascular disease. The company’s lead asset, CardiolRx, is a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation designed to target the inflammation and oxidative stress underlying conditions such as acute myocardial injury and heart failure. Cardiol holds exclusive global rights to CardiolRx through a licensing partnership and is advancing additional preclinical programs focused on small-molecule immunotherapies for heart disease.

CardiolRx is formulated for oral administration and has been evaluated in a randomized, placebo-controlled Phase 2 myocardial protection study assessing safety and key biomarkers following acute coronary syndromes.